Tofacitinib Analogs as Oxacillin Potentiators against MRSA
托法替尼类似物作为抗 MRSA 的苯唑西林增效剂
基本信息
- 批准号:10607433
- 负责人:
- 金额:$ 4.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2024-01-31
- 项目状态:已结题
- 来源:
- 关键词:ADME StudyAddressAminesAnimal TestingAnti-Bacterial AgentsAnti-Infective AgentsAntibiotic ResistanceAntibioticsAntimicrobial ResistanceAreaBindingBiochemicalBiologicalBiological AssayBiological AvailabilityBiophysicsCategoriesCell physiologyChemicalsChemistryChemosensitizationClinicalCommunitiesComplementDangerousnessDaptomycinDevelopmentDoseDrug KineticsDrug resistanceGenetic TranscriptionGentian VioletGenus staphylococcusHealthcareHouse miceHumanIn VitroIntravenousJanus kinaseLeadLeadershipLibrariesLinezolidLuciferasesMeasuresMentorsMethicillinMicrobial BiofilmsMicrobiologyMindModernizationMolecular TargetOralOxacillinPathway interactionsPharmaceutical PreparationsPhosphorylationPhosphotransferasesPrevalencePreventionProkaryotic CellsPropertyProteomicsPublic HealthResearchResistanceResourcesSaint Jude Children&aposs Research HospitalSepsisSeriesSignal TransductionSignal Transduction PathwayStaphylococcus aureusStaphylococcus aureus infectionStomachSystemSystems DevelopmentTechniquesTherapeuticTrainingValidationVancomycinVirulenceWorkWorld Health Organizationanalogantimicrobialbeta-Lactamsbiophysical analysiscare burdenclinical developmentdrug discoverydrug resistant pathogenefficacy studyexperimental studygene complementationhigh throughput screeningin vivoin vivo evaluationinterestkinase inhibitorknockout genemethicillin resistant Staphylococcus aureusmicrobialmortalitymouse modelnovelpharmacologicresponseskillssmall moleculesmall molecule librariestranscriptomics
项目摘要
Project Summary
Methicillin (oxacillin)-resistant Staphylococcus aureus (MRSA) infections are among the most frequently
occurring and dangerous antibiotic-resistant public health threat. Clinical resistance to all front-line MRSA
antibiotics (i.e. vancomycin, linezolid, daptomycin, and ceftaroline) has been observed, further exacerbating
this threat and highlighting the urgent need for new strategies to overcome drug resistance in S. aureus. In
recent years, there has been increased interest in targeting signal transduction systems for development as
antimicrobials and anti-virulence agents. Targeting bacterial signal transduction is attractive because these
systems are essential for many cellular processes in prokaryotes, and signal transduction pathways have been
extensively studied in eukaryotic systems, as evidenced by the availability of chemical libraries containing
small molecule probes with kinase inhibitor-like properties. With this strategy in mind, we screened a focused
set of kinase inhibitors and identified tofacitinib, an antirheumatic Janus kinase inhibitor, as a potential
chemistry starting point for the discovery of beta-lactam potentiators against MRSA. Several pyrrolopyridin-4-
amine (P4A) analogs of tofacitinib were synthesized, which led to the discovery of potent analogs with the
ability to re-sensitize oxacillin (OXA; a beta-lactam antibiotic) against MRSA. Preliminary pull-down proteomic
experiments have identified PurM, SrrB, and PknB as putative targets, studies that have been complemented
by gene knockout experiments. Therefore, the main scientific objective of this proposal is to confirm P4A
engagement of putative targets using biophysical and biochemical techniques and to establish the
therapeutic potential of tofacitinib analogs as anti-virulence agents and OXA potentiators against
MRSA. In Aim 1, I will evaluate the binding of lead P4A compounds to putative targets, demonstrate inhibition
of S. aureus kinase activity and determine the extent of potential off-target effects on mammalian kinases.
Biophysical assays will be developed against the putative targets through a novel target engagement assay,
which will be complemented with biochemical phosphorylation and ATP/ADP conversion assays. In Aim 2, I
will evaluate the clinical potential of the P4A compounds through anti-biofilm studies, pharmacological ADME
profiling, and in vivo efficacy against MRSA in a mouse model. The research plan will enhance my training in
areas of target identification and validation, biophysical analysis, and anti-infective microbiology, benefiting
from the expertise of my co-mentors, Drs. Richard Lee and Jason Rosch, and the state-of-the-art resources at
St. Jude.
项目摘要
耐甲氧西林金黄色葡萄球菌(MRSA)感染是最常见的
正在发生的和危险的抗药性公共卫生威胁。对所有一线MRSA的临床耐药性
已观察到抗生素(即万古霉素、利奈唑胺、达托霉素和头孢洛林),进一步加重
这一威胁,并强调迫切需要新的战略,以克服耐药性在S。金黄色。在
近年来,人们对靶向信号转导系统的开发越来越感兴趣,
抗微生物剂和抗毒性剂。靶向细菌信号转导是有吸引力的,因为这些
系统对于原核生物中的许多细胞过程是必不可少的,并且信号转导途径已经被
在真核系统中进行了广泛的研究,如化学文库的可用性所证明的,
具有类似激酶抑制剂性质的小分子探针。考虑到这一战略,我们筛选了一个重点
一组激酶抑制剂,并确定托法替尼,一种抗风湿Janus激酶抑制剂,作为一种潜在的
发现抗MRSA的β-内酰胺增效剂的化学起点。几种吡咯并吡啶-4-
合成了托法替尼的胺(P4 A)类似物,这导致发现了具有托法替尼的有效类似物。
使苯唑西林(OXA;一种β-内酰胺抗生素)对MRSA重新敏感的能力。初步下拉蛋白质组学
实验已经确定PurM、SrrB和PknB为假定的靶点,
通过基因敲除实验。因此,本提案的主要科学目标是确认P4 A
使用生物物理和生物化学技术参与推定的靶点,并建立
托法替尼类似物作为抗病毒剂和OXA增效剂的治疗潜力
耐甲氧西林金黄色葡萄球菌在目标1中,我将评估P4 A先导化合物与推定靶点的结合,证明抑制
色葡萄金黄色葡萄球菌激酶活性,并确定对哺乳动物激酶的潜在脱靶效应的程度。
将通过一种新的靶点结合试验,
其将用生化磷酸化和ATP/ADP转化测定来补充。在目标2中,我
将通过抗生物膜研究、药理学ADME和药物代谢试验评估P4 A化合物的临床潜力。
在小鼠模型中的抗MRSA的体内功效。研究计划将加强我的训练,
目标识别和验证、生物物理分析和抗感染微生物学领域,
得益于我的共同导师Richard Lee博士和Jason Rosch博士的专业知识以及
圣裘德
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gregory Phelps其他文献
Gregory Phelps的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 4.37万 - 项目类别:
Research Grant